This work is licensed under the Creative Commons Attribution 4.0 International License.
Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(10):1242–54.ChioncelOMebazaaAHarjolaVPCoatsAJPiepoliMFCrespo-LeiroMG.Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry.Eur J Heart Fail.2017;19(10):1242–54.Search in Google Scholar
Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med. 2017;377(20):1964–75.EllisonDHFelkerGM.Diuretic treatment in heart failure.N Engl J Med.2017;377(20):1964–75.Search in Google Scholar
Rubio-Gracia J, Demissei BG, Ter Maaten JM, Cleland JG, O’Connor CM, Metra M, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185–91.Rubio-GraciaJDemisseiBGTer MaatenJMClelandJGO’ConnorCMMetraM.Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure.Int J Cardiol.2018;258:185–91.Search in Google Scholar
Kazory A. Combination diuretic therapy to counter renal sodium avidity in acute heart failure: trials and tribulations. Clin J Am Soc Nephrol. 2023 Apr 27. doi: 10.2215/CJN.0000000000000188.KazoryA.Combination diuretic therapy to counter renal sodium avidity in acute heart failure: trials and tribulations.Clin J Am Soc Nephrol.2023Apr27. doi:10.2215/CJN.0000000000000188.Open DOISearch in Google Scholar
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895–e1032.HeidenreichPABozkurtBAguilarDAllenLAByunJJColvinMM.2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines.Circulation.2022May3;145(18):e895–e1032.Search in Google Scholar
McDonagh TA, Metra M, Adamo M, Baumbach A, Böhm M, Burri H, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.McDonaghTAMetraMAdamoMBaumbachABöhmMBurriH.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur Heart J.2021;42(36):3599–726.Search in Google Scholar
Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342–433.EzekowitzJAO’MearaEMcDonaldMAAbramsHChanMDucharmeA.2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure.Can J Cardiol.2017;33(11):1342–433.Search in Google Scholar
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797–805.FelkerGMLeeKLBullDARedfieldMMStevensonLWGoldsmithSRNHLBI Heart Failure Clinical Research Network.Diuretic strategies in patients with acute decompensated heart failure.N Engl J Med.2011Mar3;364(9):797–805.Search in Google Scholar
Hoorn EJ, Ellison DH. Diuretic resistance. Am J Kidney Dis. 2017;69(1):136–42.HoornEJEllisonDH.Diuretic resistance.Am J Kidney Dis.2017;69(1):136–42.Search in Google Scholar
Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Feb;21(2):137–55.MullensWDammanKHarjolaVPMebazaaABrunner-La RoccaHPMartensP.The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail.2019Feb;21(2):137–55.Search in Google Scholar
Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 1989;83(1):113–26.EllisonDHVelazquezHWrightFS.Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion.J Clin Invest.1989;83(1):113–26.Search in Google Scholar
Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco-Bacik MA, Wilson FP, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28(11):3414–24.RaoVSPlanavskyNHanbergJSAhmadTBrisco-BacikMAWilsonFP.Compensatory distal reabsorption drives diuretic resistance in human heart failure.J Am Soc Nephrol.2017;28(11):3414–24.Search in Google Scholar
Wile D. Diuretics: a review. Ann Clin Biochem. 2012 Jul;49(5):419–31.WileD.Diuretics: a review.Ann Clin Biochem.2012Jul;49(5):419–31.Search in Google Scholar
Eknoyan G. A history of diuretics. In: Seldin D, Giebisch GBT-DA, editors. Diuretic agents. San Diego: Academic Press; 1997. p. 3–28.EknoyanG.A history of diuretics. In:SeldinDGiebischGBT-DA, editors.Diuretic agents.San Diego:Academic Press;1997. p.3–28.Search in Google Scholar
Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis. 1994 May;23(5):623–43.EllisonDH.Diuretic drugs and the treatment of edema: from clinic to bench and back again.Am J Kidney Dis.1994May;23(5):623–43.Search in Google Scholar
Lang H-J, Hropot M. Discovery and development of diuretic agents. In: Greger RF, Knauf H, Mutschler E, editors. Berlin, Heidelberg: Springer Berlin Heidelberg; 1995. p. 141–72.LangH-JHropotM.Discovery and development of diuretic agents. In:GregerRFKnaufHMutschlerE, editors.Berlin, Heidelberg:Springer Berlin Heidelberg;1995. p.141–72.Search in Google Scholar
Brater DC. Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011 Nov;31(6):483–94.BraterDC.Update in diuretic therapy: clinical pharmacology.Semin Nephrol.2011Nov;31(6):483–94.Search in Google Scholar
Bernstein PL, Ellison DH. Diuretics and salt transport along the nephron. Semin Nephrol. 2011 Nov;31(6):475–82.BernsteinPLEllisonDH.Diuretics and salt transport along the nephron.Semin Nephrol.2011Nov;31(6):475–82.Search in Google Scholar
Vardanyan R, Hruby V. Chapter 21 - Diuretics. In: Synthesis of best-seller drugs, Vardanyan R, Hruby VBT-S of B-SD, editors. Boston: Academic Press; 2016. p. 317–27.VardanyanRHrubyV.Chapter 21 - Diuretics. In:Synthesis of best-seller drugs,VardanyanRHrubyVBT-S of B-SD, editors.Boston:Academic Press;2016. p.317–27.Search in Google Scholar
Novak JE, Ellison DH. Diuretics in states of volume overload: core curriculum 2022. Am J Kidney Dis. 2022;80(2):264–76.NovakJEEllisonDH.Diuretics in states of volume overload: core curriculum 2022.Am J Kidney Dis.2022;80(2):264–76.Search in Google Scholar
Fallahzadeh MA, Dormanesh B, Fallahzadeh MK, Roozbeh J, Fallahzadeh MH, Sagheb MM. Acetazolamide and hydrochlorothiazide followed by furosemide versus furosemide and hydrochlorothiazide followed by furosemide for the treatment of adults with nephrotic edema: a randomized trial. Am J Kidney Dis. 2017 Mar;69(3):420–7.FallahzadehMADormaneshBFallahzadehMKRoozbehJFallahzadehMHSaghebMM.Acetazolamide and hydrochlorothiazide followed by furosemide versus furosemide and hydrochlorothiazide followed by furosemide for the treatment of adults with nephrotic edema: a randomized trial.Am J Kidney Dis.2017Mar;69(3):420–7.Search in Google Scholar
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute cecompensated heart failure with volume overload. N Engl J Med. 2022 Sep;387(13):1185–95.MullensWDauwJMartensPVerbruggeFHNijstPMeekersE.Acetazolamide in acute cecompensated heart failure with volume overload.N Engl J Med.2022Sep;387(13):1185–95.Search in Google Scholar
Ghezzi C, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018 Oct;61(10):2087–97.GhezziCLooDDFWrightEM.Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.Diabetologia.2018Oct;61(10):2087–97.Search in Google Scholar
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.AnkerSDButlerJFilippatosGFerreiraJPBocchiEBöhmM.Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med.2021;385(16):1451–61.Search in Google Scholar
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PerkovicVJardineMJNealBBompointSHeerspinkHJLCharytanDM.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med.2019;380(24):2295–306.Search in Google Scholar
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.PackerMAnkerSDButlerJFilippatosGPocockSJCarsonP.Cardiovascular and renal outcomes with empagliflozin in heart failure.N Engl J Med.2020;383(15):1413–24.Search in Google Scholar
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.SolomonSDMcMurrayJJVClaggettBde BoerRADeMetsDHernandezAF.Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N Engl J Med.2022;387(12):1089–98.Search in Google Scholar
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.HeerspinkHJLStefánssonBVCorrea-RotterRChertowGMGreeneTHouF-F.Dapagliflozin in patients with chronic kidney disease.N Engl J Med.2020;383(15):1436–46.Search in Google Scholar
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644–57.NealBPerkovicVMahaffeyKWde ZeeuwDFulcherGEronduNShawWLawGDesaiMMatthewsDRCANVAS Program Collaborative Group.Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med.2017Aug17;377(7):644–57.Search in Google Scholar
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):323–34.WannerCInzucchiSELachinJMFitchettDvon EynattenMMattheusMEMPA-REG OUTCOME Investigators.Empagliflozin and progression of kidney disease in type 2 diabetes.N Engl J Med.2016Jul28;375(4):323–34.Search in Google Scholar
Dharia A, Khan A, Sridhar VS, Cherney DZI. SGLT2 inhibitors: the sweet success for kidneys. Annu Rev Med. 2023 Jan;74(1):369–84.DhariaAKhanASridharVSCherneyDZI.SGLT2 inhibitors: the sweet success for kidneys.Annu Rev Med.2023Jan;74(1):369–84.Search in Google Scholar
Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019 Feb;20(3):629.AnsaryTMNakanoDNishiyamaA.Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system.Int J Mol Sci.2019Feb;20(3):629.Search in Google Scholar
Guo L, Fu B, Liu Y, Hao N, Ji Y, Yang H. Diuretic resistance in patients with kidney disease: challenges and opportunities. Biomed Pharmacother. 2023 Jan;157:114058.GuoLFuBLiuYHaoNJiYYangH.Diuretic resistance in patients with kidney disease: challenges and opportunities.Biomed Pharmacother.2023Jan;157:114058.Search in Google Scholar
Titko T, Perekhoda L, Drapak I, Tsapko Y. Modern trends in diuretics development. Eur J Med Chem. 2020;208:112855.TitkoTPerekhodaLDrapakITsapkoY.Modern trends in diuretics development.Eur J Med Chem.2020;208:112855.Search in Google Scholar
Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022;13:800490.TangJYeLYanQZhangXWangL.Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism.Front Pharmacol.2022;13:800490.Search in Google Scholar
Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome. Indian J Pediatr. 2020 Aug;87(8):633–40.MeenaJBaggaA.Current perspectives in management of edema in nephrotic syndrome.Indian J Pediatr.2020Aug;87(8):633–40.Search in Google Scholar
Braunwald E. Responsiveness to loop diuretics in heart failure. Eur Heart J. 2014 May;35(19):1235–7.BraunwaldE.Responsiveness to loop diuretics in heart failure.Eur Heart J.2014May;35(19):1235–7.Search in Google Scholar
Patschan D, Patschan S, Buschmann I, Ritter O. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44(4):457–64.PatschanDPatschanSBuschmannIRitterO.Loop diuretics in acute kidney injury prevention, therapy, and risk stratification.Kidney Blood Press Res.2019;44(4):457–64.Search in Google Scholar
Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet. 1996 Mar;30(3):229–49.SicaDAGehrTW.Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.Clin Pharmacokinet.1996Mar;30(3):229–49.Search in Google Scholar
Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part I: Mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf. 2010 Mar;9(2):243–57.SarafidisPAGeorgianosPILasaridisAN.Diuretics in clinical practice. Part I: Mechanisms of action, pharmacological effects and clinical indications of diuretic compounds.Expert Opin Drug Saf.2010Mar;9(2):243–57.Search in Google Scholar
Arroyo JP, Ronzaud C, Lagnaz D, Staub O, Gamba G. Aldosterone paradox: differential regulation of ion transport in distal nephron. Physiology. 2011 Apr;26(2):115–23.ArroyoJPRonzaudCLagnazDStaubOGambaG.Aldosterone paradox: differential regulation of ion transport in distal nephron.Physiology.2011Apr;26(2):115–23.Search in Google Scholar
Reddy P, Mooradian AD. Diuretics: an update on the pharmacology and clinical uses. Am J Ther. 2009;16(1):74–85.ReddyPMooradianAD.Diuretics: an update on the pharmacology and clinical uses.Am J Ther.2009;16(1):74–85.Search in Google Scholar
Qavi AH, Kamal R, Schrier RW. Clinical use of diuretics in heart failure, cirrhosis, and nephrotic syndrome. Int J Nephrol. 2015;2015:975934.QaviAHKamalRSchrierRW.Clinical use of diuretics in heart failure, cirrhosis, and nephrotic syndrome.Int J Nephrol.2015;2015:975934.Search in Google Scholar
Jentzer JC, Dewald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010 Nov;56(19):1527–34.JentzerJCDewaldTAHernandezAF.Combination of loop diuretics with thiazide-type diuretics in heart failure.J Am Coll Cardiol.2010Nov;56(19):1527–34.Search in Google Scholar
Tanaka M, Oida E, Nomura K, Nogaki F, Fukatsu A, Uemura K, et al. The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema. Clin Exp Nephrol. 2005;9(2):122–6.TanakaMOidaENomuraKNogakiFFukatsuAUemuraK.The Na+-excreting efficacy of indapamide in combination with furosemide in massive edema.Clin Exp Nephrol.2005;9(2):122–6.Search in Google Scholar
Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997 Mar;29(3):367–72.KnaufHMutschlerE.Sequential nephron blockade breaks resistance to diuretics in edematous states.J Cardiovasc Pharmacol.1997Mar;29(3):367–72.Search in Google Scholar
Sica DA, Moser M. Diuretic therapy in cardiovascular disease. In: Black HR, Elliott WJBT-H, editors. Hypertension: a companion to Braunwald’s heart disease. Philadelphia: W.B. Saunders; 2007. p. 213–30.SicaDAMoserM.Diuretic therapy in cardiovascular disease. In:BlackHRElliottWJBT-H, editors.Hypertension: a companion to Braunwald’s heart disease.Philadelphia:W.B. Saunders;2007. p.213–30.Search in Google Scholar
Sun Q, Sever P. Amiloride: a review. J Renin Angiotensin Aldosterone Syst. 2020 Oct–Dec;21(4):1470320320975893.SunQSeverP.Amiloride: a review.J Renin Angiotensin Aldosterone Syst.2020Oct–Dec;21(4):1470320320975893.Search in Google Scholar
Hinrichs GR, Mortensen LA, Jensen BL, Bistrup C. Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome: a case report. Physiol Rep. 2018 Jun;6(12):e13743.HinrichsGRMortensenLAJensenBLBistrupC.Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome: a case report.Physiol Rep.2018Jun;6(12):e13743.Search in Google Scholar
Hoorn EJ, Ellison DH. Diuretic resistance. Am J Kidney Dis. 2017 Jan;69(1):136–42.HoornEJEllisonDH.Diuretic resistance.Am J Kidney Dis.2017Jan;69(1):136–42.Search in Google Scholar
Seay NW, Lehrich RW, Greenberg A. Diagnosis and management of disorders of body tonicity—hyponatremia and hypernatremia: core curriculum 2020. Am J Kidney Dis. 2020 Feb;75(2):272–86.SeayNWLehrichRWGreenbergA.Diagnosis and management of disorders of body tonicity—hyponatremia and hypernatremia: core curriculum 2020.Am J Kidney Dis.2020Feb;75(2):272–86.Search in Google Scholar
Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006 Sep;73(SUPPL.3):S24–S33.VerbalisJG.AVP receptor antagonists as aquaretics: review and assessment of clinical data.Cleve Clin J Med.2006Sep;73(SUPPL.3):S24–S33.Search in Google Scholar
Nistor I, Bararu I, Apavaloaie MC, Voroneanu L, Donciu MD, Kanbay M, et al. Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol. 2015 Feb;47(2):335–44.NistorIBararuIApavaloaieMCVoroneanuLDonciuMDKanbayM.Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials.Int Urol Nephrol.2015Feb;47(2):335–44.Search in Google Scholar
Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, et al. Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail. 2015 Sep;8(5):997–1005.FelkerGMMentzRJAdamsKFColeRTEgnaczykGFPatelCB.Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials.Circ Heart Fail.2015Sep;8(5):997–1005.Search in Google Scholar
Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, et al. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–406.FelkerGMMentzRJColeRTAdamsKFEgnaczykGFFiuzatM.Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure.J Am Coll Cardiol.2017;69(11):1399–406.Search in Google Scholar
Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, et al. Short-term effects of tolvaptan in Ppatients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69(11):1409–19.KonstamMAKiernanMChandlerADhingraRModyFVEisenH.Short-term effects of tolvaptan in Ppatients with acute heart failure and volume overload.J Am Coll Cardiol.2017;69(11):1409–19.Search in Google Scholar
Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020 Mar;8(3):157–68.CoxZLHungRLenihanDJTestaniJM.Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial.JACC Heart Fail.2020Mar;8(3):157–68.Search in Google Scholar
Alicic RZ, Johnson EJ, Tuttle KR. SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review. Am J Kidney Dis. 2018;72(2):267–77.AlicicRZJohnsonEJTuttleKR.SGLT2 Inhibition for the prevention and treatment of diabetic kidney disease: a review.Am J Kidney Dis.2018;72(2):267–77.Search in Google Scholar
Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018 Feb 10;7(4):e007046.WilcoxCSShenWBoultonDWLeslieBRGriffenSC.Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects.J Am Heart Assoc.2018Feb10;7(4):e007046.Search in Google Scholar
Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, et al. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol - Ren Physiol. 2020;319(4):F712–28.OnishiAFuYPatelRDarshiMCrespo-MasipMHuangW.A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.Am J Physiol - Ren Physiol.2020;319(4):F712–28.Search in Google Scholar
Mullens W, Schulze PC, Westphal J, Bogoviku J, Bauersachs J. Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice. Eur Heart J. 2023;44(24):2159–69.MullensWSchulzePCWestphalJBogovikuJBauersachsJ.Great debate: in patients with decompensated heart failure, acetazolamide in addition to loop diuretics is the first choice.Eur Heart J.2023;44(24):2159–69.Search in Google Scholar
Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22.DammanKBeusekampJCBoorsmaEMSwartHPSmildeTDJElvanA.Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur J Heart Fail.2020;22(4):713–22.Search in Google Scholar
Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated Hheart failure (EMPAG-HF). Circulation. 2022;146(4):289–98.SchulzePCBogovikuJWestphalJAftanskiPHaertelFGrundS.Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated Hheart failure (EMPAG-HF).Circulation.2022;146(4):289–98.Search in Google Scholar
Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J. 2023;44(1):41–50.BiegusJVoorsAACollinsSPKosiborodMNTeerlinkJRAngermannCE.Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial.Eur Heart J.2023;44(1):41–50.Search in Google Scholar
Brisco-Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc. 2018;7(18):e009149.Brisco-BacikMATer MaatenJMHouserSRVedageNARaoVAhmadT.Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis.J Am Heart Assoc.2018;7(18):e009149.Search in Google Scholar
Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, et al. Treatment Effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial. J Am Soc Nephrol. 2023;34(2):322–32.RefardtJImberCNobbenhuisRSailerCOHaslbauerAMonneratS.Treatment Effect of the SGLT2 inhibitor empagliflozin on chronic syndrome of inappropriate antidiuresis: results of a randomized, double-blind, placebo-controlled, crossover trial.J Am Soc Nephrol.2023;34(2):322–32.Search in Google Scholar
Refardt J, Imber C, Sailer CO, Jeanloz N, Potasso L, Kutz A, et al. A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis. J Am Soc Nephrol. 2020;31(3):615–24.RefardtJImberCSailerCOJeanlozNPotassoLKutzA.A randomized trial of empagliflozin to increase plasma sodium levels in patients with the syndrome of inappropriate antidiuresis.J Am Soc Nephrol.2020;31(3):615–24.Search in Google Scholar
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021;42(48):4891–901.NeuenBLOshimaMPerkovicVAgarwalRArnottCBakrisG.Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.Eur Heart J.2021;42(48):4891–901.Search in Google Scholar
Cooper LB, Mentz RJ, Gallup D, Lala A, DeVore AD, Vader JM, et al. Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes. J Card Fail. 2016;22(9):738–42.CooperLBMentzRJGallupDLalaADeVoreADVaderJM.Serum bicarbonate in acute heart failure: relationship to treatment strategies and clinical outcomes.J Card Fail.2016;22(9):738–42.Search in Google Scholar
Vader JM, LaRue SJ, Stevens SR, Mentz RJ, DeVore AD, Lala A, et al. Timing and causes of readmission after acute heart failure hospitalization—insights from the Hheart failure network trials. J Card Fail. 2016;22(11):875–83.VaderJMLaRueSJStevensSRMentzRJDeVoreADLalaA.Timing and causes of readmission after acute heart failure hospitalization—insights from the Hheart failure network trials.J Card Fail.2016;22(11):875–83.Search in Google Scholar
Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M, et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur J Heart Fail. 2019;21(11):1415–22.VerbruggeFHMartensPAmelootKHaemelsVPendersJDupontM.Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance.Eur J Heart Fail.2019;21(11):1415–22.Search in Google Scholar
Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020;180(5):718–26.QiaoYShinJIChenTKInkerLACoreshJAlexanderGC.Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate.JAMA Intern Med.2020;180(5):718–26.Search in Google Scholar
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 Sep 2;341(10):709–17.PittBZannadFRemmeWJCodyRCastaigneAPerezAPalenskyJWittesJ.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.N Engl J Med.1999Sep2;341(10):709–17.Search in Google Scholar
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543–51.JuurlinkDNMamdaniMMLeeDSKoppAAustinPCLaupacisA.Rates of hyperkalemia after publication of the randomized aldactone evaluation study.N Engl J Med.2004;351(6):543–51.Search in Google Scholar
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252–63.PittBFilippatosGAgarwalRAnkerSDBakrisGLRossingP.Cardiovascular Events with finerenone in kidney disease and type 2 diabetes.N Engl J Med.2021;385(24):2252–63.Search in Google Scholar
Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, et al. Real-world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22):e012655.LindeCBakhaiAFurulandHEvansMMcEwanPAyoubkhaniD.Real-world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom.J Am Heart Assoc.2019;8(22):e012655.Search in Google Scholar
Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos GS, et al. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure LongTerm Registry. Eur J Heart Fail. 2020;22(8):1378–89.RossignolPLainscakMCrespo-LeiroMGLarocheCPiepoliMFFilippatosGS.Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure LongTerm Registry.Eur J Heart Fail.2020;22(8):1378–89.Search in Google Scholar
Grodin JL, Stevens SR, De Las Fuentes L, Kiernan M, Birati EY, Gupta D, et al. Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure. J Card Fail. 2016;22(1):26–32.GrodinJLStevensSRDe Las FuentesLKiernanMBiratiEYGuptaD.Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure.J Card Fail.2016;22(1):26–32.Search in Google Scholar
Trulls JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Snchez-Marteles M, Conde-Martel A, et al.; CLOROTIC trial investigators. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023 Feb 1;44(5):411–421.TrullsJCMorales-RullJLCasadoJCarrera-IzquierdoMSnchez-MartelesMConde-MartelACLOROTIC trial investigators.Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial.Eur Heart J.2023Feb1;44(5):411–421.Search in Google Scholar
Emmens JE, Ter Maaten JM, Matsue Y, Figarska SM, Sama IE, Cotter G, et al. Worsening renal function in acute heart failure in the context of diuretic response. Eur J Heart Fail. 2022;24(2):365–74.EmmensJETer MaatenJMMatsueYFigarskaSMSamaIECotterG.Worsening renal function in acute heart failure in the context of diuretic response.Eur J Heart Fail.2022;24(2):365–74.Search in Google Scholar
Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–19.AgarwalRSinhaADCramerAEBalmes-FenwickMDickinsonJHOuyangF.Chlorthalidone for hypertension in advanced chronic kidney disease.N Engl J Med.2021;385(27):2507–19.Search in Google Scholar
Bovée DM, Visser WJ, Middel I, de Mik–van Egmond A, Greupink R, Masereeuw R, et al. A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease. J Am Soc Nephrol. 2020;31(3):650–62.BovéeDMVisserWJMiddelIde Mik–van EgmondAGreupinkRMasereeuwR.A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease.J Am Soc Nephrol.2020;31(3):650–62.Search in Google Scholar
Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA, et al. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol. 2017;2(9):950–8.ButlerJAnstromKJFelkerGMGivertzMMKalogeropoulosAPKonstamMA.Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial.JAMA Cardiol.2017;2(9):950–8.Search in Google Scholar
Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319–31.KonstamMAGheorghiadeMBurnettJCGrinfeldLMaggioniAPSwedbergK.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial.JAMA.2007;297(12):1319–31.Search in Google Scholar
